Could two old drugs beat long COVID? new trial aims to find out
NCT ID NCT06974084
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether two FDA-approved drugs, maraviroc and atorvastatin, can help people with Long COVID. 252 adults aged 18-65 with persistent symptoms will take either the drug combination or a placebo for 16 weeks. The main goal is to see if it reduces fatigue and improves physical and mental function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Maraviroc and Atorvastatin
What this could lead to
If it works, this could point toward a treatment for Long COVID symptoms like fatigue and brain fog using already-approved drugs.
What could go wrong
This is a Phase 2/3 trial, so it's still early. The drugs are not yet proven for Long COVID, and there is a chance they won't work better than placebo. Side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Arizona
Tucson, Arizona, 85719, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact